

Virbac Group (VIRP) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/V7DD8893DCAEN.html>

Date: May 2021

Pages: 50

Price: US\$ 125.00 (Single User License)

ID: V7DD8893DCAEN

Abstracts

Virbac Group (VIRP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Virbac Group (Virbac) is an animal health company which focuses on development and production of vaccines and medicines for domestic animals and livestock. It manufactures pet medications such as vaccines, antibiotics, parasiticides, dental products, nutrition, diagnosis, anti-inflammatory drugs and dermatological products. Virbac's products include ear cleanser for dogs and cats; food supplement for cattle; tablets for the prevention of canine heartworm disease and treatment of roundworms and hookworms; general anesthetics and others. The company operates manufacturing, research and development, and subsidiaries across Europe, North America, Asia-Pacific, Latin America, Africa and the Middle East. Virbac is headquartered in Carros Cedex, France.

Virbac Group Key Recent Developments

Apr 15,2021: Virbac: very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven by very solid performance in all areas

Jul 20,2020: Virbac: Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year

Apr 15,2020: Virbac: 2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying

Apr 15,2020: Virbac: 2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying

Mar 16,2020: Virbac: 2019 operating profit from ordinary activities on the rise

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage,

financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Virbac Group - Key Facts
Virbac Group - Key Employees
Virbac Group - Key Employee Biographies
Virbac Group - Major Products and Services
Virbac Group - History
Virbac Group - Company Statement
Virbac Group - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Virbac Group - Business Description
Business Segment: Companion Animals
Overview
Performance
Business Segment: Food Producing Animals
Overview
Performance
Business Segment: Other Businesses
Performance
Geographical Segment: Africa & Middle East
Performance
Geographical Segment: Asia
Performance
Geographical Segment: Europe (excluding France)
Performance
Geographical Segment: France
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: North America
Performance
Geographical Segment: Pacific

Performance
R&D Overview
Virbac Group - Corporate Strategy
Virbac Group - SWOT Analysis
SWOT Analysis - Overview
Virbac Group - Strengths
Virbac Group - Weaknesses
Virbac Group - Opportunities
Virbac Group - Threats
Virbac Group - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Virbac Group, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Virbac Group, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Virbac Group, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 15, 2021: Virbac: very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven by very solid performance in all areas

Jul 20, 2020: Virbac: Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year

Apr 15, 2020: Virbac: 2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying

Apr 15, 2020: Virbac: 2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying

Mar 16, 2020: Virbac: 2019 operating profit from ordinary activities on the rise

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Virbac Group, Key Facts
Virbac Group, Key Employees
Virbac Group, Key Employee Biographies
Virbac Group, Major Products and Services
Virbac Group, History
Virbac Group, Subsidiaries
Virbac Group, Key Competitors
Virbac Group, Ratios based on current share price
Virbac Group, Annual Ratios
Virbac Group, Annual Ratios (Cont...1)
Virbac Group, Annual Ratios (Cont...2)
Virbac Group, Interim Ratios
Virbac Group, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Virbac Group, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Virbac Group, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Virbac Group, Performance Chart (2016 - 2020)

Virbac Group, Ratio Charts

Virbac Group, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Virbac Group, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Virbac Group (VIRP) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/V7DD8893DCAEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V7DD8893DCAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970